Dengue Traveler
Vaccines Forecast
Dengue is the second most common specific cause of fever diagnosed in ill returned travelers worldwide, after malaria alone, and the single most common cause among travelers returning from Southeast Asia and South Central Asia. 2024 was the worst year for dengue on record, with more than 14 million cases reported worldwide, and elevated transmission has persisted into 2025/26. Yet the current vaccine landscape still is not built for the traveler segment: Sanofi is discontinuing Dengvaxia in 2026, and Takeda's newer Qdenga (TAK-003) remains guided, in practice, toward travelers with confirmed prior dengue infection rather than the first-time exposure typical of most Western visitors. This is a comprehensive, traveler-specific commercial assessment of that opportunity, drawing on VacZine Analytics' long standing, independent authority in travel disease vaccine markets.
- Format
- Executive presentation + Excel model
- Coverage
- 85 countries, from major Western origins
- Traveler types
- Vacation, VFR & business
- Forecast horizon
- To 2030
- Approach
- Value/volume by type & serostatus
- Base edition
- Feb 2018, updated Aug 2026
- Availability
- Syndicated / bespoke
ill returned travelers, after malaria
in 2024, a record year
covered in this traveler model
segment vaccine demand
A leading cause of travel-related fever, still without a traveler-suited vaccine
This review sets out dengue's role in traveler-importation dynamics, a historical European case study, and the record case surges of recent years, before turning to how well (or poorly) today's licensed and pipeline vaccines actually fit the traveler segment.
Pathogen overview - Dengue virus (DENV-1 to DENV-4) in the traveler segment
Dengue Fever (DF) is a mosquito-borne disease, transmitted by Aedes mosquitoes and caused by single-strand RNA viruses of the family Flaviviridae. Among ill returned travelers, dengue is the second most common specific cause of febrile illness worldwide, after malaria alone, and the single most common cause of fever among travelers returning from Southeast Asia and South Central Asia, a pattern that has held consistently across successive multi-year surveillance periods. The disease poses a risk not only to the individual traveler but also to public health more broadly: returning viraemic travelers can seed onward transmission wherever a competent Aedes vector population is already established.
Madeira, Portugal (2012-13) remains the clearest European case study of that importation pathway. Local Aedes aegypti populations, combined with viraemic arrivals, produced an autochthonous outbreak of roughly 2,000 cases, the largest of its kind recorded in the EU. With Aedes albopictus now established across much of southern and even central Europe, and further northward range creep documented in recent years, the underlying risk pathway that produced Madeira's outbreak has, if anything, widened rather than receded.
Recent case-surge data reinforce that picture at global scale. 2024 was the worst year for dengue on record: more than 14 million cases were reported worldwide across upward of 100 countries, more than double the total recorded in 2023, itself a previous record year. The World Health Organization and the Pan American Health Organization attribute the surge to a combination of urbanisation, El Nino-linked climate variability and rising temperatures, which have already increased the transmission potential of Aedes aegypti by an estimated 42.7% since the 1950s, and continuing Aedes range expansion into previously unaffected latitudes. 2025 brought a substantial pullback in the Americas, down around two-thirds from 2024's peak, but global case counts still exceeded 5 million across some 106 countries and territories through early December 2025, with all four dengue serotypes co-circulating simultaneously, a configuration that keeps outbreak potential, and traveler risk from major Western source markets, elevated.
A vaccine landscape still built around prior exposure, not first-time travelers
Sanofi's Dengvaxia is exiting the market just as Takeda's Qdenga (TAK-003, previously known during earlier development as DenVax) expands internationally, but neither vaccine, nor the field's remaining pipeline candidates, is straightforwardly suited to the first-time-exposure profile typical of most Western travelers.
-
Sanofi PasteurDiscontinuing, Q3 2026Dengvaxia (CYD-TDV) 3-dose, 0/6/12-month schedule
Sanofi is discontinuing global production of Dengvaxia due to low demand; existing lots expire in August 2026 and will not be replaced. The vaccine was never well suited to travelers, given its long three-dose schedule and, since 2018, a label restriction to individuals with laboratory-confirmed prior dengue infection, a screening hurdle most travelers cannot clear before departure. -
TakedaApproved, 40+ countriesQdenga (TAK-003) Live-attenuated, 2-dose, 3 months apart
EU approved since 2022 and now authorized across more than 40 countries in Europe, Latin America and Asia, including the UK, Brazil, Argentina, Indonesia, Thailand and India. In the US, Takeda voluntarily withdrew its FDA application in 2023 after the agency requested additional data beyond the pivotal TIDES trial; no US approval has followed, and resubmission timing remains unclear. Qdenga's label in most approved markets does not mandate pre-vaccination screening, a genuine advantage over Dengvaxia's screen-and-vaccinate approach, but travel-medicine bodies have so far applied their own caution: the UK's JCVI/NaTHNaC guidance recommends Qdenga for travelers only where a previous dengue infection is confirmed, stating that current trial data remain insufficient to recommend it to seronegative travellers. In September 2026, Takeda entered an exclusive agreement with Dr Reddy's Laboratories to promote and distribute Qdenga across India's private paediatric and adult market, with availability expected from H1 2027 subject to further regulatory steps, a further sign of Qdenga's continuing international commercial rollout in a major VFR-travel source and destination market. -
NIH / Instituto ButantanApproved Brazil, suspended Jun 2026TetraVax-DV (TV003/TV005), marketed in Brazil as Butantan-DV
A single-dose, live-attenuated tetravalent candidate licensed from the US NIH. Brazil's health authorities approved Butantan-DV in December 2025 for individuals aged 12-59, but the Brazilian Ministry of Health temporarily suspended its use in June 2026 pending an investigation into adverse event reports, alongside continued Bangladesh Phase II follow-up of TV005. This remains the field's most credible longer-term rival to Qdenga, though it is not yet positioned or labelled specifically for the traveler segment, and the suspension is a reminder of the safety-data bar any new entrant must clear first. -
Walter Reed Army Institute of ResearchDiscontinuedTDENV-PIV (purified inactivated vaccine)
This tetravalent purified-inactivated candidate progressed through early-phase testing with GSK adjuvant systems but has since been discontinued and is no longer an active traveler-segment contender. -
UK NaTHNaC/JCVI, US CDC/ACIP, ECDC, Australia ATAGIActive guidance trackingTravel-medicine body recommendations
National travel-health authorities continue to update country-specific dengue vaccination guidance season by season as Qdenga's international approvals expand and Dengvaxia is phased out, an evolving picture this analysis tracks closely. In a June 2026 review of its Country Information pages, the UK's NaTHNaC/UKHSA extended a dengue vaccine recommendation (for eligible travellers) to most destinations with a known dengue risk, while confirming that around eight lower-risk destinations, including the USA, Spain, Italy, France and Australia, still carry no vaccine recommendation and remain covered only under general "other risks" advice; the underlying Qdenga eligibility criteria for UK travellers were not changed by this update. Australia became Qdenga's latest travel-relevant market in 2026: following TGA approval in April, the Australian Technical Advisory Group on Immunisation (ATAGI) issued dedicated travel guidance in September recommending a risk-based approach that reaches beyond confirmed prior infection, covering travellers with a previous dengue history, long-term or repeat travellers to endemic destinations and, following individual risk-benefit assessment, some shorter trips, a notably broader traveler remit than the UK's confirmed-prior-infection-only stance. Qdenga became available to order through Australian GP/travel clinics from 1 October 2026, via private prescription outside the National Immunisation Program.
Dengvaxia's exit and Qdenga's international rollout have not, in practice, opened the traveler segment as widely as the headline regulatory picture suggests. The world's two licensed dengue vaccines both concentrate protection on individuals with confirmed prior dengue infection, one by explicit label restriction, the other by cautious travel-medicine guidance layered on top of a more permissive label. That leaves a genuine, quantifiable gap for a first-time-infection-friendly vaccine among the vacation, VFR and business travelers who make up the bulk of Western dengue exposure. The VacZine Analytics model sizes both that opportunity and the addressable population actually captured under current guidance, by traveler type and serostatus, to 2030.
Six analytical layers - one traveler-segment picture
This is a genuinely traveler-specific report, spanning disease burden, competitor and guidance tracking, and scenario-based demand forecasting from major Western points of origin to 85 countries with ongoing transmission, to 2030.
Value ($m) and volume (mio doses) demand modelling to 2030, from major Western points of origin to 85 countries with ongoing dengue transmission.
Full comparison of Dengvaxia, Qdenga, TetraVax-DV and TDENV-PIV against the specific needs of the traveler segment.
Vacation, visiting friends/family (VFR) and business/other traveler segments, each split by first-time and repeat/experienced serostatus.
Traveler-importation dynamics, the Madeira 2012-13 case study, and updated global burden data through the 2024 record case surge and 2025/26 season.
Country-by-country dengue vaccination recommendation status from UK NaTHNaC/JCVI, US CDC/ACIP and ECDC, tracked as guidance evolves.
Designed as an ideal tool to aid early-stage decision making in dengue traveler-vaccine positioning, investment and market entry planning.
A glimpse of the commercial model
The table below shows a partial view of the traveler-type and geography framework. Full volume/value outputs, serostatus splits and country-level data are in the licensed model.
| Traveler type | Geography of origin | Destination region | Vaccine suitability | Revenue scenario |
|---|---|---|---|---|
| Vacation travelers | US, UK & Western Europe | Southeast Asia | Qdenga (confirmed prior infection only) | Modelled |
| Visiting friends/family (VFR) | US, Canada & Western Europe | South Central Asia & Caribbean | Qdenga (confirmed prior infection only) | Modelled |
| Business & other travel | Major Western origin markets | Latin America & Sub-Saharan Africa | No vaccine currently recommended (seronegative) | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All origins | All destinations | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the dengue traveler vaccine opportunity.
- Executive presentation (~80 slides) - disease background, traveler-importation epidemiology, the Madeira 2012-13 case study, and full competitor and guidance landscape review
- MS-Excel workbooks (~90 worksheets) - value ($m) and volume (mio doses) predictions to 2030 by traveler type and serostatus
- 85-country traveler-origin demand model - from major Western points of origin to all countries with ongoing dengue transmission
- Competitor intelligence - Dengvaxia's confirmed 2026 discontinuation, Qdenga's international rollout, and TetraVax-DV's Phase III progress
- Travel-medicine guidance tracker - country-by-country recommendation status from UK NaTHNaC/JCVI, US CDC/ACIP and ECDC, tracked as it evolves
- Updated epidemiology module - the record 2024 global case surge and continued elevated transmission through the 2025/26 season
Built for organisations evaluating the dengue traveler vaccine opportunity
Most valuable to teams assessing the traveler-specific dengue vaccine market against their own pipeline, travel-health service line or investment thesis, now that Dengvaxia is exiting and Qdenga's international footprint is expanding.
Vaccine developers
Target product profile and positioning guidance for a genuinely first-time-infection-friendly traveler vaccine candidate.
Travel medicine & occupational health providers
Independent benchmarking of vaccine suitability across traveler types, to support clinic-level advice as guidance evolves.
Investors & analysts
Independent read on Qdenga's international commercial trajectory and the commercial gap left by Dengvaxia's exit.
Corporate travel & duty-of-care programmes
Business-traveler risk assessment and vaccination-policy planning across high-transmission destination regions.
Public health & travel-health policy bodies
Supporting evidence base for country-level travel vaccination guidance development as the competitive landscape shifts.
Researchers & academia
Comprehensive traveler-importation epidemiology and serostatus segmentation for grant and translational planning.
VacZine Analytics has a long standing expertise in travel diseases, tracking the dengue traveler vaccine opportunity since our original February 2018 edition, well before Qdenga's international approval and long before Sanofi confirmed Dengvaxia's discontinuation. This is a genuinely traveler-specific analysis, distinct from broader endemic-market dengue coverage, and it has been well received by clients for the depth of its traveler-type and serostatus segmentation. Few groups have followed this specific segment as closely, and that recognised, independent expertise underpins everything in the analysis.
This February 2018 edition has been updated, August 2026, to incorporate the record 2024 global case surge, Qdenga's expanding international approvals and current travel-medicine guidance, and Dengvaxia's confirmed 2026 discontinuation. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc dengue traveler-vaccine analysis, a briefing call is included on request.